Picture loading failed.

Anti-CD3E;MS4A1 therapeutic antibody (Pre-made Mosunetuzumab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-356-1mg 1mg 3090
GMP-Bios-ab-356-10mg 10mg 21890
GMP-Bios-ab-356-100mg 100mg 148000
GMP-Bios-ab-356-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD3E;MS4A1 therapeutic antibody (Pre-made Mosunetuzumab biosimilar,Bispecific mAb)
INN Name Mosunetuzumab
TargetCD3E;MS4A1
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;4k7p:YX
Year Proposed2017
Year Recommended2018
CompaniesGenentech
Conditions Approvedna
Conditions ActiveDiffuse large B cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Follicular lymphoma
Conditions Discontinuedna
Development Techna